Health Care · Pharmaceutical Preparations

DNTH Dianthus Therapeutics, Inc. /DE/ SEC Filings & Insider Trading Activity 2026

company
CIK 1690585111 filings
Russell 2000

DNTH at a glance

Dianthus Therapeutics, Inc. /DE/ (DNTH, SEC CIK 1690585) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.0 million (down 67.3% from FY2024) and a net loss of $162.3 million. Diluted EPS was -$4.20.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Dianthus Therapeutics, Inc. /DE/ (DNTH) shares worth $1.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Savitz Ryan on November 12, 2026 of 17,724 shares at $90.56 per share.
  • In the last 90 days, DNTH insiders reported 0 open-market purchases ($0) and 17 open-market sales ($15.7M) on Form 4, a net sale of $15.7M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.0M
−67.3% vs prior year
Insiders · 90 days
0 buys · 17 sells
Net −$15.7M
13F holders
29 funds
$1.6B · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development of claseprubart and DNTH212 biopharmaceutical candidates reliant on outsourced manufacturing and clinical trial services
  • New emphasis: Impact of the BIOSECURE Act (Dec 2025) restricting collaborations with certain Chinese biotech firms, including sole manufacturer WuXi Biologics
  • Strategic risk shift: Heightened regulatory and geopolitical exposure due to reliance on Chinese contract manufacturers amid increasing U.S.-China trade tensions
  • Notable metric: Sole supplier WuXi Biologics in China for claseprubart, with significant supply chain and regulatory risks highlighted in detail
  • Unusual fact: First-year reporting impact of U.S. BIOSECURE Act posing potential federal contract and funding prohibitions involving designated Chinese "biotechnology companies of concern"

Risk Factors

  • Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
  • Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million
  • Operational risk: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with no owned laboratory or manufacturing facilities
  • Competitive risk: Significant R&D spending $145.6M in 2025 to advance claseprubart and DNTH212 amid competition from other biopharma firms in autoimmune neurology space
  • Financial risk: Net loss $162.3M in 2025 with cash runway into 2028; future capital needs may dilute shareholders via ATM $200M equity offering capacity

Management Discussion & Analysis

  • Net loss reported; specific profitability or margin figures not provided
  • No segment performance data detailed
  • Cash flow usage: capital expenditures and operating expenses incurred, no buybacks or dividends mentioned
  • Forward-looking: general caution on risks and uncertainties, no specific guidance or outlook disclosed

AI summary of the DNTH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors from the December 31, 2025 Form 10-K
  • Carried-forward risk: unidentified risks could materially harm business, financial condition, results and growth prospects
  • Market risk: adverse developments could reduce the market price of common stock

Management Discussion & Analysis

  • Quarterly revenue $1.2M vs $0.4M YoY, up $0.8M from reimbursable claseprubart trial costs
  • Operating margin not meaningful, operating loss $58.5M vs $40.3M YoY
  • R&D expenses $45.6M vs $32.5M, driven by claseprubart trials and DNTH212/DNTH312 discovery
  • Operating cash flow used $128.2M through nine months, vs $82.1M YoY
  • Cash, equivalents and investments $1.2B, funding expected into 2030; CAPTIVATE results projected by year-end 2027

AI summary of the DNTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results
  • Exhibit 99.1 contains the detailed earnings figures and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 net loss $46.6M, or $0.81 per share, versus $36.8M, or $0.97, year over year
  • Cash, equivalents and investments $1.2B at September 30, 2026, supporting projected runway into 2030
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results released for quarter ended June 30, 2026
  • Full financial results and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 net loss $50.2M, or $0.90/share, versus $31.6M, reflecting sharply higher development spending
  • R&D expense $48.7M, up from $26.3M, as Phase 2 and Phase 3 claseprubart programs accelerate
Filed Jun 12, 2026Full analysis →

Item 8.01: Other Events

  • June 2026 corporate presentation filed as Exhibit 99.1, potentially updating investors on Dianthus’s strategy and pipeline
  • Filing signed June 12, 2026 by Adam M. Veness, SVP, General Counsel and Secretary

Item EX-99.1: Item EX-99.1

  • Claseprubart Phase 2 gMG results support potential best-in-disease positioning, with statistically significant improvements across five key efficacy measures at 300mg/2mL Q2W
  • 65 participants enrolled; 300mg/2mL achieved MG-ADL change of -4.6 vs -2.8 for placebo at Week 13

AI summaries of DNTH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DNTH

Don't miss the next DNTH filing

  • Alerts as it files. A push when DNTH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DNTH, by share count.
  • Ask anything. An AI agent that reads every DNTH filing and answers with sources.

DNTH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Savitz RyanMNov 12, 2026$22.07
Savitz RyanSellNov 12, 2026$90.56
Savitz RyanMNov 12, 2026-
Savitz RyanMNov 12, 2026-
Savitz RyanMNov 12, 2026$21.77
Savitz RyanMNov 11, 2026$22.07
Savitz RyanMNov 11, 2026-
Savitz RyanSellNov 11, 2026$90.03

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.8M$6.2M$2.0M
Operating Income-$48.2M-$101.9M-$177.9M
Net Income-$43.6M-$85.0M-$162.3M
Op. Margin-1704.7%-1633.7%-8739.3%
Net Margin-1541.2%-1362.8%-7973.3%
Balance Sheet
Total Assets$179.4M$374.0M$530.9M
Equity-$352.5M$493.4M
ROE--24.1%-32.9%
Per Share
EPS$-8.45$-2.55$-4.20
Cash Flow
Operating CF-$36.9M-$78.2M-$129.1M

Source: XBRL data in Dianthus Therapeutics, Inc. /DE/ (DNTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DNTH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DNTH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$1.60B
Q2 202631$2.41B
Q1 202629$1.78B
Q4 202523$685.8M
Q3 202524$507.2M
Q2 202521$191.8M
Q1 202516$139.5M
Q4 202414$167.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DNTH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Sep 18, 2026--
4Sep 3, 2026--
4Aug 19, 2026--
4Aug 14, 2026--
SC 13GAug 13, 2026-
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 7, 2026--
SC 13GAug 7, 2026-
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 13, 2026--
4Jun 18, 2026--
8-KJun 12, 2026Analysis-
4Jun 2, 2026-
4May 22, 2026-
4May 22, 2026-
8-KMay 22, 2026Analysis
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-

Related Health Care companies

All Health Care →

DNTH SEC filings: frequently asked questions

Are DNTH insiders buying or selling?

In the last 90 days, Dianthus Therapeutics, Inc. /DE/ (DNTH) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $15.7 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold DNTH stock?

As of September 30, 2026, the largest Dianthus Therapeutics, Inc. /DE/ (DNTH) holders among the 13F filers tracked by SignalX were BlackRock ($386.5 million), State Street Corp ($223.1 million), Vanguard Capital Management LLC ($213.8 million), T. Rowe Price Group ($194.4 million), Vanguard Portfolio Management LLC ($136.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DNTH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.0 million (down 67.3% from FY2024) and a net loss of $162.3 million. Diluted EPS was -$4.20. The figures come from the XBRL data in the 10-K.

What are the main risks in DNTH's latest 10-K?

In the 10-K filed March 9, 2026, Dianthus Therapeutics, Inc. /DE/ (DNTH) flagged: Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals. Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million. (AI summary of the Risk Factors section.)

What did DNTH report in its latest 8-K?

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results.

What are the latest DNTH SEC filings?

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.

What is DNTH's SEC CIK number?

Dianthus Therapeutics, Inc. /DE/ (DNTH)'s SEC Central Index Key (CIK) is 1690585. EDGAR lists every DNTH filing under that number.

Ask anything about DNTH

The research agent reads DNTH's filings, financials, insider trades and 13F holders, then answers with sources.